Featured Story

  • AbbVie buys API plant in Singapore where it's already building one

    When AbbVie announced its plans for a $320 million bulk manufacturing facility in Singapore in February, it said it would be its first in Asia when it was ready to roll near the end of the decade. But the drugmaker has now picked up a smaller API plant in Singapore and it will be up and running in 2016.

Baxter labeling issue could leave patients short on potassium chloride

For the second time in four months, Baxter International finds itself recalling highly concentrated potassium chloride. This time it's a labeling problem, one that the company says has the potential to be life-threatening.

Merck KGaA to power India plant with coconut and cashew shells

Next year, Merck KGaA plans to start a biomass heating plant in the U.S. but for now is starting on a project in India that will use cashew and coconut shells, recycling a local waste product into biomass fuel.

Some Aurobindo epilepsy capsules found empty, prompting recall

India's Aurobindo has recalled a lot of an epilepsy drug because some of the capsules contain no drug at all.

Merck manufacturing know-how brought to bear on NewLink Ebola vaccine

NewLink Genetics, the small Iowa company working on a promising Ebola vaccine, has been looking for manufacturing muscle, not to mention development experience and marketing know-how, to get its Ebola vaccine to market.

Amgen opens $200M continuous purification plant in Singapore

Amgen CEO Robert Bradway hinted several years ago that the company was on the "cusp" of a new manufacturing process for making cell-based drugs that would upend the industry, being faster and cheaper. Today, Amgen said that time has arrived, with completion in Singapore of a $200 million plant that incorporates continuous processing.